Inventiva S.A.
NASDAQ:IVABiotechnology
+$0.02 today
- Market cap
- $176.22M
- Beta
- 0.88
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.56
Volume 3.54M
Average 0.45M
IVA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Inventiva S.A.NASDAQ: IVA
Revenue · Q4 FY2025 · quarter ended Dec 2025
Revenue declines year over year
Q4 FY2025 revenue of €28.79K fell 99.6% year over year. Over 3 fiscal years it compounded at -28.3% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 9 analysts of €3.68M (-17.9%) for the fiscal year ending Dec 2026, a step up from the -51.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- €28.79K— QoQ
- Last fiscal yearDec 2025
- €4.48M-51.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -99.6% | — | — |
| 1 year | -51.3% | -17.9% | +33.4 pp |
| 3-year CAGR | -28.3% | +206.5% | +234.8 pp |
| 5-year CAGR | +168.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
EUR · from the income statement
- Latest · FY2025
- 4.48M EUR
- Year-over-year change
- -51.3%
- 4-year CAGR
- +1.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.48M | -51.3% |
| FY2024 | 2024-12-31 | 9.2M | -47.4% |
| FY2023 | 2023-12-31 | 17.48M | +43.5% |
| FY2022 | 2022-12-31 | 12.18M | +190.4% |
| FY2021 | 2021-12-31 | 4.19M | — |
Revenue vs competitors
How IVA compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -51.3% is the 5th highest of 7, against a peer median of +10.2%.
- Over three fiscal years its annual growth of -28.3% compares with a peer median of -8.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $69.21M USD | +7.4% | -8.8% | |
| LTM Mar 2026 | $55.87M USD | +52.3% | — | |
| LTM Mar 2026 | $32.72M USD | +1033.9% | +111.6% | |
| LTM Mar 2026 | $11.2M USD | +13.0% | -7.0% | |
| FY2025 | €4.48M EUR | -51.3% | -28.3% | |
| LTM Mar 2026 | $1.78M USD | -94.8% | -70.7% | |
| LTM Mar 2026 | $225K USD | — | — | |
| LTM Mar 2026 | $59K USD | -86.6% | -85.2% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $0 USD | — | — |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding IVA) | — | +10.2% | -8.8% | |
Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.19M | 12.18M | 17.48M | 9.2M | 4.48M |
| Cost of Revenue | 1.02M | 995K | (23K) | 3.88M | 2.8M |
| Gross Profit | 4.19M | 17.06M | 17.5M | 9.2M | 1.51M |
| Gross Margin | 100.0% | 140.1% | 100.1% | 100.0% | 33.7% |
| Research & Development | 48.45M | 60.47M | 110.01M | 90.88M | 83.61M |
| Selling, General & Admin | 11.52M | 15.5M | 15.61M | 17.1M | 53.89M |
| Operating Expenses | 56.31M | 74.17M | 120.19M | 106.76M | 137.37M |
| Depreciation & Amortization | 858K | 870K | 2.6M | 5.2M | 2.8M |
| EBITDA | (52.76M) | (56.29M) | (102.04M) | (166.53M) | (128.15M) |
| EBITDA Margin | -1258.0% | -462.2% | -583.9% | -1810.4% | -2858.6% |
| Operating Income | (52.11M) | (57.11M) | (102.71M) | (97.56M) | (130.95M) |
| Operating Margin | -1242.6% | -468.9% | -587.7% | -1060.6% | -2921.0% |
| Interest Income | 57K | 390K | 945K | 1.14M | 2.83M |
| Interest Expense | 138K | 707K | 5.18M | 12.18M | 32.3M |
| Other Income / Expenses | 2.84M | 2.82M | (7.11M) | (86.34M) | (211.38M) |
| Income Before Tax | (49.27M) | (54.29M) | (109.82M) | (183.9M) | (342.33M) |
| Pre-Tax Margin | -1174.8% | -445.8% | -628.4% | -1999.4% | -7636.1% |
| Income Tax Expense | 364K | (20K) | 607K | 313K | 22K |
| Net Income | (49.64M) | (54.27M) | (110.43M) | (184.21M) | (340.16M) |
| Net Margin | -1183.5% | -445.6% | -631.8% | -2002.7% | -7587.8% |
| EPS (Basic) | (1.27) | (1.31) | (2.43) | (3.54) | (1.82) |
| EPS (Diluted) | (1.27) | (1.31) | (2.43) | (3.54) | (1.82) |
| Weighted Avg Shares | 39.17M | 41.45M | 45.35M | 51.98M | 186.8M |
| Weighted Avg Shares (Diluted) | 39.17M | 41.45M | 45.35M | 51.98M | 186.8M |
Inventiva S.A.
NASDAQ:IVA
Intrinsic Alpha fair value
Locked
Current Price
$3.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.